Innovation in Blood Cancer

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.

Joshua Richter, MD, is Associate Professor of Medicine in The Tisch Cancer Institute, Division of Hematology and Medical Oncology. He is the director of Multiple Myeloma at the Blavatnik Family- Chelsea Medical Center at Mount Sinai. Dr. Richter treats patients with plasma cell dyscrasias, including multiple myeloma and related diseases such as AL amyloidosis, plasma cell leukemia, and Waldenstrom’s Macroglobulinemia. Dr. Richter has extensive experience with clinical trials focused on novel therapies, including antibody therapy and immunotherapy for a precision medicine approach. He has published extensively on these topics and has been invited to speak regionally, nationally, and also internationally. He has been published in journals such as the New England Journal of Medicine, Blood, and the Journal of Clinical Oncology.

Dr. Tremblay has led multi-institutional research efforts in myeloproliferative neoplasms and is actively involved in both investigator-initiated and industry sponsored early and late phase clinical trials in myeloid neoplasms. Dr. Tremblay specializes in hematologic malignancies including acute myeloid leukemia, myeloproliferative neoplasms and myelodysplastic syndromes.

Dr. Thomas Habermann is a Professor of Medicine at Mayo Clinic College of Medicine, Chair of the Nominating Committee of the ECOG-ACRIN, and the Chair of the Mayo Clinic Lymphoma Tumor Board since 2014. He is board certified in internal medicine and hematology and has published extensively on lymphoma, leukemia, and hematologic malignancies. Dr. Habermann has received numerous awards since joining the Mayo Clinic faculty in 1985 and has been an author on over 400 papers, 38 book chapters, and 7 books. He has also been a member of the B-Cell National Comprehensive Cancer Network guidelines committee since 2014. Dr. Habermann has received numerous honors and awards for his teaching and research, including the Henry S. Plummer Distinguished Physician Award, the 2012 Lifetime Achievement for Outstanding Contributions to Medical Education Award, and the Mayo Clinic Distinguished Educator Award. He has served as the education program director, the head of section, and the associate chair of education in the Division of Hematology, and as the associate dean of internal medicine and medical subspecialties in the Mayo Graduate School of Medicine. He is an active member and leader of several professional societies and committees, such as the American Society of Clinical Oncology, the American Society of Hematology, the Lymphoma Research Foundation, the Eastern Cooperative Oncology Group, and the North Central Cancer Treatment Group. Dr. Habermann has published extensively on topics related to lymphoma, leukemia, hairy cell leukemia, post-transplant lymphoproliferative disorders, and hematologic malignancies.

John Mascarenhas, MD, is a Professor of Medicine at the Icahn School of Medicine at Mount Sinai. Dr. Mascarenhas is the Director of the Center of Excellence for Blood Cancers and Myeloid Disorders, directs the Adult Leukemia Program, and is a member of The Tisch Cancer Institute. His clinical and research focus centers around myeloproliferative neoplasms (MPNs) and acute myeloid leukemia (AML). Throughout his illustrative career, Dr. Mascarenhas has published over 275 papers, is the principal investigator for the National Cancer Institute sponsored Myeloproliferative Disease Research Consortium, and has served as principal investigator or study chair on numerous clinical trials geared toward innovative treatment approaches for MPNs and AML. Dr. Mascarenhas is widely recognized for his work in MPNs and is often invited to speak at conferences for his expertise in the field.